

Alberta Drug Benefit List (ADBL) interim update now available online

Please be advised that the **September 1, 2024** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at ab.bluecross.ca/dbl/publications.php.

Please refer to the **September 1, 2024** updates for complete listings of products available by special authorization, restricted benefit/special authorization, added products, new established interchangeable groupings, least cost alternative price changes, products with a price change and discontinued products.

Please note that the online *interactive Drug Benefit List (iDBL)* at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Removal of temporary benefit from the ADBL

Due to the shortage of Dexamethasone Sodium Phosphate 10 mg/ml Injection (DIN 00874582) manufactured by Sandoz Canada Inc., **Dexamethasone Omega 10 mg/ml Injection (DIN 02204274)** was added as a temporary benefit for the *ADBL*.

Alberta Blue Cross® has confirmed that the shortage Dexamethasone Sodium Phosphate 10 mg/ml Injection (DIN 00874582) has been resolved.

Dexamethasone Omega 10 mg/ml Injection (DIN 02204274) will no longer be considered a temporary benefit for the *ADBL* **after September 23, 2024**. The above grouping was removed from the Critical Supply Product List **August 21, 2024**.

continued next page

continued from previous page

Product supply shortage addressed for ADBL

Alberta Blue Cross has confirmed that the shortages for Apo-Candesartan 32 mg Tablet (DIN 02541319), Candesartan 32 mg Tablet (DIN 02435845) manufactured by Sanis Health Inc., Candesartan 32 mg Tablet (DIN 02528266) manufactured by Sivem Pharmaceuticals ULC., Mint-Candesartan 32 mg Tablet (DIN 02476932), pms-Candesartan 32 mg Tablet (DIN 02391228), Sandoz Candesartan 32 mg Tablet (DIN 02417340) and Teva-Candesartan 32 mg Tablet (DIN 02366339) have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 25, 2024**. The following grouping was removed from the Critical Supply Product List **August 26, 2024**.

CANDESARTAN CILEXETIL

32 MG TABLET

00002399105	APO-CANDESARTAN	APX	\$ 0.2281
00002541319	APO-CANDESARTAN	APX	\$ 0.2281
00002445816	AURO-CANDESARTAN	AUR	\$ 0.2281
00002435845	CANDESARTAN	SNS	\$ 0.2281
00002528266	CANDESARTAN	SIV	\$ 0.2281
00002379295	CANDESARTAN CILEXETIL	AHI	\$ 0.2281
00002386534	JAMP-CANDESARTAN	JPC	\$ 0.2281
00002476932	MINT-CANDESARTAN	MPI	\$ 0.2281
00002527030	NRA-CANDESARTAN	NRA	\$ 0.2281
00002391228	PMS-CANDESARTAN	PMS	\$ 0.2281
00002380714	RAN-CANDESARTAN	RAN	\$ 0.2281
00002417340	SANDOZ CANDESARTAN	SDZ	\$ 0.2281
00002366339	TEVA-CANDESARTAN	TEV	\$ 0.2281
00002311658	ATACAND	CAG	\$ 1.3999

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

